Search

Your search keyword '"Silva-Barbosa, Suse"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Silva-Barbosa, Suse" Remove constraint Author: "Silva-Barbosa, Suse"
44 results on '"Silva-Barbosa, Suse"'

Search Results

1. Enhanced Migratory Capacity of T Lymphocytes in Severe Chagasic Patients Is Correlated With VLA-4 and TNF-α Expression

4. Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

6. Additional file 1: Figure S1. of HAM/TSP-derived HTLV-1-infected T cell lines promote morphological and functional changes in human astrocytes cell lines: possible role in the enhanced T cells recruitment into Central Nervous System

7. Additional file 2: Figure S2. of HAM/TSP-derived HTLV-1-infected T cell lines promote morphological and functional changes in human astrocytes cell lines: possible role in the enhanced T cells recruitment into Central Nervous System

8. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

15. Chagasic Thymic Atrophy Does Not Affect Negative Selection but Results in the Export of Activated CD4+CD8+ T Cells in Severe Forms of Human Disease

16. Immunoendocrinology of the Thymus in Chagas Disease

23. CD4+CD25High Treg cells in HIV/HTLV Co-infected patients with neuropathy: high expression of Alpha4 integrin and lower expression of Foxp3 transcription factor.

28. Chagasic Thymic Atrophy Does Not Affect Negative Selection but Results in the Export of Activated CD4+CD8+ T Cells in Severe Forms of Human Disease.

30. Additional file 4: Figure S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

31. Additional file 1: Table S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

32. Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

33. Additional file 6: Figure S3. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

34. Additional file 2: Table S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

35. Additional file 3: Table S3. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

36. Additional file 2: Table S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

37. Additional file 7: Figure S4. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

38. Additional file 6: Figure S3. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

39. Additional file 3: Table S3. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

40. Additional file 5: Figure S2. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

41. Additional file 4: Figure S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

42. Additional file 1: Table S1. of CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

43. The Involvement of Laminin in Anti-Myocardial Cell Autoimmune Response in Murine Chagas Disease

44. Is there a role for fibronectin upon true histiocytic lymphoma progression?

Catalog

Books, media, physical & digital resources